S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Laser breakthrough could send stock soaring 2,467% (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Laser breakthrough could send stock soaring 2,467% (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Laser breakthrough could send stock soaring 2,467% (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Laser breakthrough could send stock soaring 2,467% (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company

Prothena (PRTA) Stock Forecast, Price & News

$69.01
+2.62 (+3.95%)
(As of 06/2/2023 ET)
Compare
Today's Range
$66.37
$69.08
50-Day Range
$47.66
$78.59
52-Week Range
$21.06
$79.65
Volume
436,735 shs
Average Volume
484,957 shs
Market Capitalization
$3.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$86.33

Prothena MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
25.1% Upside
$86.33 Price Target
Short Interest
Bearish
6.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Prothena in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$15.09 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.98) to ($4.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

364th out of 983 stocks

Pharmaceutical Preparations Industry

170th out of 486 stocks


PRTA stock logo

About Prothena (NASDAQ:PRTA) Stock

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

PRTA Stock News Headlines

15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
CORPORATE OVERVIEW
Prothena (NASDAQ:PRTA) Price Target Raised to $120.00
Prothena (NASDAQ:PRTA) Shares Gap Up to $52.51
Prothena (NASDAQ:PRTA) Given Outperform Rating at SVB Leerink
Prothena (NASDAQ:PRTA) Rating Reiterated by SVB Leerink
See More Headlines

PRTA Price History

PRTA Company Calendar

Last Earnings
5/04/2023
Today
6/02/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRTA
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$86.33
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+25.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-116,950,000.00
Net Margins
-232.19%
Pretax Margin
-250.21%

Debt

Sales & Book Value

Annual Sales
$54.92 million
Book Value
$11.51 per share

Miscellaneous

Free Float
37,876,000
Market Cap
$3.64 billion
Optionable
Optionable
Beta
0.36

Key Executives

  • Gene G. KinneyGene G. Kinney
    President, Chief Executive Officer & Director
  • Brandon S. Smith
    Chief Operating Officer
  • Tran B. Nguyen
    Chief Financial & Strategy Officer
  • Wagner M. ZagoWagner M. Zago
    Chief Scientific Officer
  • Hideki Garren
    Chief Medical Officer













PRTA Stock - Frequently Asked Questions

Should I buy or sell Prothena stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRTA shares.
View PRTA analyst ratings
or view top-rated stocks.

What is Prothena's stock price forecast for 2023?

9 Wall Street analysts have issued 1 year price objectives for Prothena's shares. Their PRTA share price forecasts range from $55.00 to $120.00. On average, they predict the company's stock price to reach $86.33 in the next twelve months. This suggests a possible upside of 25.1% from the stock's current price.
View analysts price targets for PRTA
or view top-rated stocks among Wall Street analysts.

How have PRTA shares performed in 2023?

Prothena's stock was trading at $60.25 at the start of the year. Since then, PRTA shares have increased by 14.5% and is now trading at $69.01.
View the best growth stocks for 2023 here
.

When is Prothena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our PRTA earnings forecast
.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) issued its quarterly earnings data on Thursday, May, 4th. The biotechnology company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.06. The biotechnology company had revenue of $2.17 million for the quarter, compared to analysts' expectations of $7.53 million. Prothena had a negative trailing twelve-month return on equity of 24.99% and a negative net margin of 232.19%. Prothena's revenue for the quarter was up 88.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.78) earnings per share.

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Who are Prothena's major shareholders?

Prothena's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (12.82%), BlackRock Inc. (6.87%), Price T Rowe Associates Inc. MD (6.07%), Wellington Management Group LLP (4.30%), State Street Corp (3.99%) and Palo Alto Investors LP (3.15%). Insiders that own company stock include Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen and Wagner M Zago.
View institutional ownership trends
.

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $69.01.

How much money does Prothena make?

Prothena (NASDAQ:PRTA) has a market capitalization of $3.64 billion and generates $54.92 million in revenue each year. The biotechnology company earns $-116,950,000.00 in net income (profit) each year or ($2.62) on an earnings per share basis.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for the company is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at ellen.rose@prothena.com, or via fax at 353-1902-3510.

This page (NASDAQ:PRTA) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -